PMID- 18556231
OWN - NLM
STAT- MEDLINE
DCOM- 20081103
LR  - 20080922
IS  - 1262-3636 (Print)
IS  - 1262-3636 (Linking)
VI  - 34
IP  - 4 Pt 1
DP  - 2008 Sep
TI  - Aggressive multimodal therapy of sporadic malignant insulinoma can improve 
      survival: a retrospective 35-year study of 12 patients.
PG  - 343-8
LID - 10.1016/j.diabet.2008.01.013 [doi]
AB  - AIM: Sporadic malignant insulinoma (SMI) is a rare disease, and the consequent 
      paucity of data in the literature and the development of aggressive treatments 
      for liver metastases have led us to retrospectively analyze a series of 12 cases 
      of SMI. METHODS: Every patient presenting with SMI, according to the WHO 2004 
      histopathology criteria, between 1970 and June 2005 in Marseille was included in 
      the study. Patients with multiple endocrine neoplasia type 1 (MEN-1) and tumours 
      of uncertain malignant potential were excluded. RESULTS: The ratio of male/female 
      was 4/8, and mean age at diagnosis was 52.5 years. A 48-h fasting test in 10 
      patients was conclusive in nine, after a mean duration of 12 h 45 min. SMI size 
      ranged from 7-120 mm (mean 30.3mm). Six patients had liver metastases and one had 
      isolated lymph-node invasion. Surgery was performed in 12 patients. Five 
      persisting diseases (mean follow-up of 1.8 years) required other treatments 
      (chemoembolization, radiofrequency thermoablation [RFTA], liver transplantation); 
      one patient relapsed 8.5 years after surgery; six were still in complete 
      remission (mean follow-up of 5.8 years), and one patient had died by the time of 
      the 24-month follow-up. CONCLUSION: Aggressive sequential multimodal therapy can 
      prolong the survival of patients with SMI even in the presence of liver 
      metastases.
FAU - Begu-Le Corroller, A
AU  - Begu-Le Corroller A
AD  - Service de nutrition-maladies metaboliques-endocrinologie, hopital de la Timone, 
      264, rue Saint-Pierre, 13005 Marseille, France. audrey.begu@mail.ap-hm.fr
FAU - Valero, R
AU  - Valero R
FAU - Moutardier, V
AU  - Moutardier V
FAU - Henry, J-F
AU  - Henry JF
FAU - Le Treut, Y-P
AU  - Le Treut YP
FAU - Gueydan, M
AU  - Gueydan M
FAU - De Micco, C
AU  - De Micco C
FAU - Sierra, M
AU  - Sierra M
FAU - Conte-Devolx, B
AU  - Conte-Devolx B
FAU - Oliver, C
AU  - Oliver C
FAU - Raccah, D
AU  - Raccah D
FAU - Favre, R
AU  - Favre R
FAU - Digue, L
AU  - Digue L
FAU - Heim, M
AU  - Heim M
FAU - Seitz, J-F
AU  - Seitz JF
FAU - Delpero, J-R
AU  - Delpero JR
FAU - Vialettes, B
AU  - Vialettes B
LA  - eng
PT  - Journal Article
DEP - 20080616
PL  - France
TA  - Diabetes Metab
JT  - Diabetes & metabolism
JID - 9607599
SB  - IM
MH  - Antineoplastic Combined Chemotherapy Protocols/therapeutic use
MH  - Combined Modality Therapy/mortality
MH  - Female
MH  - Follow-Up Studies
MH  - Humans
MH  - Insulinoma/mortality/secondary/surgery/*therapy
MH  - Liver Neoplasms/diagnosis/mortality/secondary/therapy
MH  - Male
MH  - Middle Aged
MH  - Pancreatic Neoplasms/mortality/surgery/*therapy
MH  - Prognosis
MH  - Retrospective Studies
MH  - Survival Rate
EDAT- 2008/06/17 09:00
MHDA- 2008/11/04 09:00
CRDT- 2008/06/17 09:00
PHST- 2007/08/03 00:00 [received]
PHST- 2008/01/28 00:00 [revised]
PHST- 2008/01/30 00:00 [accepted]
PHST- 2008/06/17 09:00 [pubmed]
PHST- 2008/11/04 09:00 [medline]
PHST- 2008/06/17 09:00 [entrez]
AID - S1262-3636(08)00093-1 [pii]
AID - 10.1016/j.diabet.2008.01.013 [doi]
PST - ppublish
SO  - Diabetes Metab. 2008 Sep;34(4 Pt 1):343-8. doi: 10.1016/j.diabet.2008.01.013. 
      Epub 2008 Jun 16.